ArticleBlood2017
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 171 citations in OpenAlex.
- Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.Cancer science · 2018Trial
- Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.Cellular immunology · 2017Trial
- Precision Immunoregulation in transplantation: The rise of engineered Treg therapies.Molecular biology reports · 2026Review
- Review
- Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategies.World journal of clinical oncology · 2025Review
- Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing.bioRxiv : the preprint server for biology · 2025Article
- Association of immune cells with the risk of basal cell carcinoma: A bidirectional Mendelian randomized study.Medicine · 2025Article
- Deubiquitinase USP24 activated by IL-6/STAT3 enhances PD-1 protein stability and suppresses T cell antitumor response.Science advances · 2025Article
- PD-1 suppresses human CD38Journal for immunotherapy of cancer · 2025Article
- Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss.International journal of molecular sciences · 2024Article
- Hematopoietic Stem Cells and Their Niche in Bone Marrow.International journal of molecular sciences · 2024Review
- Review
- Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy.Infectious agents and cancer · 2024Article
- Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Article
- Frequency of peripheral PD-1British journal of cancer · 2023Article
- Recurrent infection transiently expands human tissue T cells while maintaining long-term homeostasis.The Journal of experimental medicine · 2023Article
- A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease.Cell biology and toxicology · 2023Article
- Advances in Immunotherapy for Hepatocellular Carcinoma.Cancers · 2023Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Takeru AsanoDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yusuke MeguriDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Takanori YoshiokaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yuriko KishiDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Miki IwamotoDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Makoto NakamuraDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yasuhisa SandoDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Hideo YagitaDepartment of Immunology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
John KorethDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Haesook T KimDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA.ORCID 0000-0003-4889-6849
Edwin P AlyeaDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Corey S CutlerDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Vincent T HoDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Joseph H AntinDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Robert J SoifferDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Mitsune TanimotoDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Jerome RitzDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Harvard University · USOkayama University · JPDana-Farber Cancer Institute · USJuntendo University · JP
Funding
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5MManipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7MReconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5MNCI NIH HHS P01 CA142106NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560
Abstract
CD4
Indexed as
AnimalsAntigens, CDChronic DiseaseCTLA-4 AntigenDisease Models, Animalfas ReceptorGraft vs Host DiseaseHepatitis A Virus Cellular Receptor 2Immunologic MemoryInterleukin-2Lymphocyte Activation Gene 3 ProteinMiceMice, KnockoutPhosphorylationProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-bcl-2Antigens, CDBcl2 protein, mouseCTLA-4 AntigenFas protein, mousefas ReceptorHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Interleukin-2Lag3 protein, mouseLymphocyte Activation Gene 3 ProteinPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-bcl-2STAT5 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.